PAS Kinase Inhibition for ALS and Neurodegenerative Diseases ID: 2017-018
A novel therapeutic approach targeting PAS kinase to treat ALS and related neurodegenerative diseases.
Photo by Unai Huizi
Technology Overview
This technology focuses on the role of PAS kinase, a serine/threonine kinase that influences protein activity through phosphorylation, in neurodegenerative diseases. It identifies PAS kinase as a regulator of Ataxin-2, a protein implicated in various neurological disorders. Inhibition of PAS kinase, therefore, presents a potential strategy for ameliorating symptoms associated with Ataxin-2 overexpression, such as in ALS. The document highlights the use of BioE-115, among other inhibitors, which has shown promise in preclinical models.
Key Advantages
- Targets a novel pathway not previously exploited in ALS therapy
- Provides a new therapeutic strategy based on protein phosphorylation modulation
- Supported by in vitro and in vivo evidence demonstrating efficacy in model systems
- Potential broader application in treating various neurodegenerative diseases beyond ALS
Problems Addressed
- Lack of effective treatments for ALS and related neurodegenerative conditions
- Overexpression and dysfunction of Ataxin-2 in neurodegenerative diseases
- Limited number of therapeutic targets currently available for ALS treatment
Market Applications
- Pharmaceutical development for ALS and other neurodegenerative diseases
- Targeted therapy options for conditions associated with Ataxin-2 dysfunction
- Research and development in kinase inhibitors with neuroprotective effects
Additional Information
Technology ID: 2017-018
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report